A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Trial details
- Registry ID
- NCT06481891
- Drugs studied
- Sotagliflozin
TrialRedline tracks 4 clinical trials sponsored by Lexicon Pharmaceuticals: 1 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891 | Sotagliflozin | Active not recruiting | 2027-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)NCT06203002 | LX9211 (blinded) | Completed | 2025-01-14Actual |
| Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaNCT04662281 | LX9211 | Completed | 2022-11-18Actual |
| Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainNCT04455633 | LX9211 | Completed | 2022-05-23Actual |
Names as written in the registry records.
NCT06481891 · Lexicon Pharmaceuticals
Before: Jul 2026. After: Jan 2027.
NCT06481891 · Lexicon Pharmaceuticals
Before: Recruiting. After: Active not recruiting.
NCT04662281 · Lexicon Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in Average Daily Pain Score (ADPS). After: Measure: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS).